Truist Financial
ADAP

Truist Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

Truist Financial’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,633
Closed -$141K – 2538
2020
Q3 		$141K Buy
+17,633
New +$154K ﹤0.01% 2320

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Truist Financial's ADAP Position: Q4 2020 in Review

Truist Financial sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 17,633 shares — an estimated $141K sold.

Truist Financial first reported a position in ADAP in Q3 2020 and held it in 1 quarter. The position peaked at $141K in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Truist Financial reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Truist Financial sold 17,633 Adaptimmune Therapeutics shares in Q4 2020, an estimated $141K.
  • Truist Financial first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Truist Financial's Adaptimmune Therapeutics position peaked at $141K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Truist Financial's 13F filing for Q4 2020, filed 18 Feb 2021.